News & media
21 August 2018
Calcification propensity can be improved therapeutically
A randomized controlled trial from Denmark demonstrates, that calcification propensity can be improved by increasing dialysate magnesium. This clear effect was shown in 57 hemodialysis patients and establishes calcification propensity as a new therapeutic target. Indicating its importance, the publication in the top 10% of all research outputs ever tracked by Altmetric. (abstract podcast).
10 August 2018
Calciscon establishes reference values and new result reporting system
Calcification values from 253 healthy adults were analyzed and the reference range established between 270 and 470 minutes. To facilitate clinical use, a reciprocal Calcification Score will be derived, where one standard deviation in the population corresponds to one new Calcification Score Unit. Reference values are between 3.0 and 7.0. Higher values correspond to higher calcification propensity.
24 January 2018
Calcification time is associated with disease activity in Systemic Lupus Erythematodes
A new publication reports data on 168 Swiss patients with systemic lupus erythematodes, a systemic autoimmune disease affecting mainly younger women. This is the first report indicating that the clinical value of measuring calcification propensity/crystal formation time may reach well beyond kidney disease patients. Abstract
05 December 2017
Calciscon has measured over 20'000 research samples
Our R&D Measurement Service is increasingly requested by researchers and companies from all over the world. We have now measured the T50 values/crystal formation time in over 20'000 research samples. This demonstrates an increasing interest in this important new cardiovascular risk factor and therapeutic target.
28 November 2017
Calciscon receives the EU Seal of Excellence
The European Horizon 2020 program has recognized Calciscon by awarding its Seal of Excellence. The Seal of Excellence is the high-quality label awarded to projects submitted to Horizon 2020 which were deemed to deserve funding but did not receive it due to budget limits. This very positive evaluation demonstrates the high quality and very innovative character of Calciscon's work and product pipeline.
10 October 2017
Calciscon buys the patents for the measurement of the Calcification Test
After initially negotiating a worldwide exclusive license, we have now purchased our core patents from University of Aachen, Germany. Patents have already been granted in the EU, USA, China, Japan and Australia. Further applications are running.
19 September 2017
Calciscon is supported by be-advanced
Be-advanced, the innovation incubator of the Canton of Bern, Switzerland, supports Calciscon as one of its high-potential start-ups with its accelerator coaching program. This enables us to accelerate and streamline the going-to-market processes for our innovative products.
15 July 2017
Calciscon starts microfluidic development project
We have started an R&D project together with University of Aachen and SBU Waldheim, both Germany, to develop a point-of-care device for the measurement of T50 / crystal formation time. The project is supported by the German Ministry of Economics and has the aim to measure crystal formation time in less than 10 minutes.
02 February 2017
Calciscon has moved to Biel
As of 2.2.2017 Calciscon has moved to Biel, InnoCampus (Aarbergstrasse 5, 2560 Nidau). There is now more space available to create the future and a successful business.
17 September 2016
«…dann haben Millionen von Patienten ein besseres Leben»
14 September 2016
Calciscon is among the Top 100 Start-Ups 2016
15 January 2016
Calciscon is ISO 13485 certified
After successful implementation of its quality management system, Calciscon has received ISO 13485:2003 and EN ISO 13485:2012 certification in December 2015.
16 September 2015
Calciscon again among the Top 100 Swiss Startups
Calciscon was ranked 41 among the Top 100 Swiss Startups chosen by startup.ch in 2015.
31 July 2015
Inselspital Bern launches T50-Test
The Department of Clinical Chemistry of the University Hospital Bern (Inselspital), launches Calciscon's T50-Test for official clinical use for patients. The Inselspital info flyer can be downloaded here.
10 July 2015
CE-marked Calcification Blood Test kit available
Calciscon launches as its first product the CE-certified T50-Test kit.
23 March 2015
Calciscon closes Seed financing round
Calciscon closes a series A financing round. This will enable the company to develop and launch its CE-marked T50-Test kit in 2015 in Europe.
01 December 2014
Prof. Geoffrey A. Block joins Medical Advisory Board
We are delighted that Prof. Geoffrey Block joined Calciscon's Medical Advisory Board ....read more.
17 September 2014
Calciscon is a Swiss Top 100 startup company
Startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung. Calciscon took part in this prestigious competition for the first time in 2014 and was selected as a top 100 startup on the 38th place.
18 June 2014
Calciscon wins de Vigier entrepreneurship prize
02 June 2014
T50 test predicts survival of kidney transplanted patients
In a recently published abstract at the international ERA-EDTA Congress in Amsterdam, Keyzer et al. showed in 700 kidney transplanted patients that serum T50 is associated with mortality and graft failure…. read more
07 April 2014
Calciscon wins venture kick III entrepreneurship prize
01 March 2014
Calciscon moves into labs at University Hospital Bern
Calciscon starts its operational business in lab facilities located within the central clinical lab of University Hospital Bern, Inselspital.
18 January 2014
Calciscon establishes medical & scientific advisory board
Leading experts in the fields of clinical and basic biomineralization research join the newly established advisory board at CALCISCON...read more...
03 December 2013
Calciscon wins the Heuberger Winterthur entrepreneurship award
Calciscon wins CHF 150,000. In total, 133 projects were in competion for one of the three prestigious prizes donated by the Robert and Ruth Heuberger Foundation.
31 October 2013
T50-Test predicts survival of chronic kidney disease patients
A recently published study (Smith et al., JASN 2014) shows a close association between T50-Test and survival of CKD 3&4 patients. One hundred and eighty patients were analysed in this prospective study over 5.3 years.